Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status

Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status

Objectives Osimertinib has exhibited promising central nervous system (CNS) efficacy in Epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) patients. In real-world clinical practice, patients would turn to plasma genotyping or take osimertinib blindly after CN...

Full description

Bibliographic Details
Main Authors: Jun Liao MD, Yihua Huang MD, Jiadi Gan MD, Lanlan Pang MD, Wael A. S. Ali MD, Yunpeng Yang MD, PhD, Likun Chen MD, PhD, Li Zhang MD, PhD, Wenfeng Fang MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2022-02-01
Series:Cancer Control
Online Access:https://doi.org/10.1177/10732748221081360

Internet

https://doi.org/10.1177/10732748221081360

Similar Items